Advanced Solid Tumors Clinical Trials in San Francisco, California

7 studies are recruiting for advanced solid tumors in San Francisco, California right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study of PARG Inhibitor FORX-428 in Patients With Advanced Solid Tumors.

   The goal of this interventional study is to evaluate the safety and tolerability of escalating doses of FORX-428 as monotherapy in patients with select advanced solid tumors with BRCA1/2 mutations or other DDR deficiencies or high replication stress, and to determine the maximum tolerated dose (MTD…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of California, San Francisco, San Francisco, California

   Locations

   8 in total

   Run by

   FoRx Therapeutics AG

   See if you can join NCT07356453 on ClinicalTrials.gov

2. TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

   The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE: Due to character limits, the arms section does NOT include …

   Stage

   Phase 2

   Ages

   12 and older

   Site

   Kaiser Permanente - South San Francisco Medical Center, San Francisco, California

   Locations

   181 in total

   Run by

   American Society of Clinical Oncology

   See if you can join NCT02693535 on ClinicalTrials.gov

3. Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations

   A Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamic (PD), and preliminary antitumor activity of TYRA-430 in cancers with FGF/FGFR pathway aberrations, including locally advanced/metastatic hepatocellular carcinoma and other advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UCSF Medical Center at Mount Zion, San Francisco, California

   Locations

   16 in total

   Run by

   Tyra Biosciences, Inc

   See if you can join NCT06915753 on ClinicalTrials.gov

4. Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

   The primary goal of this study is to assess the safety and tolerability of mRNA-4359 administered alone and in combination with pembrolizumab or ipilimumab and nivolumab.

   Stage

   Phase 1

   Ages

   12 and older

   Site

   UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California

   Locations

   39 in total

   Run by

   ModernaTX, Inc.

   See if you can join NCT05533697 on ClinicalTrials.gov

5. Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

   Phase 1/2, open-label study of ETX-636 in participants with advanced solid tumors

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California

   Locations

   15 in total

   Run by

   Ensem Therapeutics

   See if you can join NCT06993844 on ClinicalTrials.gov

6. A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body

   This study is researching an experimental drug called REGN10597 alone or in combination with another drug called cemiplimab (called "study drug(s)"). The study is focused on patients with certain solid tumors that are in an advanced stage. The aim of the study is to see how safe, tolerable, and eff…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of California San Francisco (UCSF), San Francisco, California

   Locations

   11 in total

   Run by

   Regeneron Pharmaceuticals

   See if you can join NCT06413680 on ClinicalTrials.gov

7. A Study of MGC028 in Participants With Advanced Solid Tumors

   The goal of this clinical trial is to characterize the safety, tolerability, dose-limiting toxicities (DLT), and maximum tolerated dose (MTD) or maximum administered dose of MGC028 (if no MTD is defined). The study will enroll adult participants with relapsed or refractory, unresectable, locally ad…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UCSF - Helen Diller Family Cancer Center, San Francisco, California

   Locations

   7 in total

   Run by

   MacroGenics

   See if you can join NCT06723236 on ClinicalTrials.gov